

THE SEARLE COMPANY LIMITED  
One IBL Centre, 2nd Floor,  
Plot # 1, Block 7 & 8, D.M.C.H.S.,  
Tipu Sultan Road. Off Shahra-e-Faisal,  
Karachi Postal Code-75350  
UAN: (021) 111 SEARLE (732753)  
Tel: (92-21) 371 70 200, 370 70 201  
Fax: (92-21) 371 70 224, 371 70 225

Karachi-Plant  
F-319, S.I.T.E., Karachi  
Tel: 32578001 (7 lines)  
Fax: (92-21) 32564667

Lahore-Plant  
32-Km Multan Road, Lahore  
Tel: (92-42) 36169990, 36169992  
Fax: (92-42) 35380040

Dated: December 13, 2023

Ref: C/PSX-M.Info.20231213-

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Karachi.

Dear Sir,

**SEARLE**

Material Information

In accordance with section 96 of the Securities Act, 2015 and clause of 5.6.1(a) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby convey the following information:

We are pleased to share that The Searle Company Limited has received approval from the Drug Regulatory Authority of Pakistan (DRAP) for **ADALIMUMAB**, a biosimilar drug developed in collaboration with BioRay Biopharmaceuticals Co. Limited, China, this marks the first locally manufactured Monoclonal antibody (mABs) in Pakistan.

The introduction of ADALIMUMAB to the market within the next 3-6 months is a strategic move aimed at providing high-quality, affordable biotechnology medicines to patients in Pakistan. This development aligns with our commitment to diversifying our product portfolio, thereby enhancing the quality of earnings and shareholders' value.

For more details, visit [BioRay Biopharmaceuticals Co. Limited]  
(<https://www.bioraypharm.com/index.php?m=list&a=index&classid=43>)

You may please inform the TREC holders accordingly.

Yours truly,

Zubair Razzak Palwala  
Director & Company Secretary

cc: Executive Director / HOD  
Corporate Supervision Department (Company Law Division)  
Securities & Exchange Commission of Pakistan  
NIC Building, 63 Jinnah Avenue, Blue Area  
Islamabad